Non-alcoholic fatty liver disease and dyslipidemia: An updateNiki Katsiki, Christos S. Mantzoros, Dimitri P. Mikhailidis|Metabolism|2016Cited by 576
Lifestyle recommendations for the prevention and management of metabolic syndrome: an international panel recommendationPablo Pérez‐Martínez, José López‐Miranda, Montserrat Fitó et al.|Nutrition Reviews|2017Cited by 414
Non-alcoholic fatty liver disease, insulin resistance, metabolic syndrome and their association with vascular riskEmir Muzurović, Christos S. Mantzoros, Dimitri P. Mikhailidis|Metabolism|2021Cited by 343
The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel StatementVasilios G. Athyros, Christos S. Mantzoros, Theodore K. Alexandrides et al.|Metabolism|2017Cited by 251
Adiponectin, lipids and atherosclerosisNiki Katsiki, Dimitri P. Mikhailidis, Christos S. Mantzoros|Current Opinion in Lipidology|2017Cited by 171